Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Convergence is going virtual. Join the brightest minds in regulatory online to gain the latest knowledge in the field in an all-virtual experience with workshops, one-on-one expert sessions, and networking communities.
This year, our European regulatory community will converge online with a fully virtual program that will allow attendees to experience Euro Convergence live online from the safety and comfort of their homes.
RAPS' “how to” guide to developing a comprehensive global regulatory strategy for all types of medical devices. Updated September 2020.
The last exam window of 2020 is currently open. Register by 8 October to take the RAC exam this autumn.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.
Posted 15 March 2012 | By Alexander Gaffney, RAC
Outgoing Johnson & Johnson (J&J) Chief Executive Officer William Weldon will receive $143 million in retirement pay, according to a regulatory filing released by J&J.
The company-and Weldon's reputation-were plagued last year by a large number of quality setbacks that caused the US Food and Drug Administration (FDA) to take notice, including a consent decree between FDA and a Pennsylvania manufacturing plant owned by J&J subsidiary McNeil PPC.
Weldon, who has been CEO for ten years and has worked at J&J since 1971, will receive the compensation primarily as the result of deferred and long-term compensation, as well as pension benefits.
While Weldon won't see these benefits immediately-he assumed the position of Chair of the J&J Board of Directors in April-they still come "at a time when J&J is still fighting the fallout from a series of consumer-drug and device recalls," writes Fierce Pharma.
Read more:
Bloomberg - J&J CEO Weldon to Get $143.5M in Retirement
FiercePharma - J&J's Weldon due for $143M retirement package
Tags: Retiring, CEO, Weldon, McNeil, J&J, Latest News
Regulatory Focus newsletters
All the biggest regulatory news and happenings.